Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
Respira Therapeutics Enters into Agreement with Gossamer Bio Granting Gossamer Option to Acquire Respira from Samsara BioCapital
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On?Demand Vardenafil for Pulmonary Hypertension
Transition Metals Resampling Highlights Broad Gold Intervals at Gowganda Project, Indicating Potential for a Larger Resource Opportunity
Nevada Sunrise Identifies Gold-in-Soil Anomalies over New Target Areas at the Griffon Gold Mine Project, Nevada
